Drug Approval | September 26, 2025
FDA approves Alembic’s Paroxetine ER tablets
Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
_LOGO_256_384.jpg){kind=logo}
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
Ultra-high purity surfactant for biologics and parenteral drug formulations
Zydus Pinkathon will be led by women to raise awareness on breast cancer and women's health
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
The facility has been classified as Voluntary Action Indicated
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
Subscribe To Our Newsletter & Stay Updated
